Search Results - "VERMA, Udit N"

Histone H3 phosphorylation by IKK-α is critical for cytokine-induced gene expression by Gaynor, Richard B, Yamamoto, Yumi, Verma, Udit N, Prajapati, Shashi, Kwak, Youn-Tae

“…Cytokine-induced activation of the IκB kinases (IKK) IKK-α and IKK-β is a key step involved in the activation of the NF-κB pathway. Gene-disruption studies of…”
Get full text

Small Interfering RNAs Directed against β-Catenin Inhibit the in Vitro and in Vivo Growth of Colon Cancer Cells by VERMA, Udit N, SURABHI, Rama M, SCHMALTIEG, Aurelia, BECERRA, Carlos, GAYNOR, Richard B

“…The β-catenin and APC genes are key components of the Wnt signaling pathway. Mutation of these genes results in increased levels of the β-catenin protein,…”
Get full text

Enhanced Chemosensitivity to Irinotecan by RNA Interference-Mediated Down-Regulation of the Nuclear Factor-κB p65 Subunit by JUN GUO, VERMA, Udit N, GAYNOR, Richard B, FRENKEL, Eugene P, BECERRA, Carlos R

“…In preclinical tumor models, inhibition of nuclear factor-κB (NF-κB) has been associated with increased sensitivity to chemotherapeutic agents such as…”
Get full text

Sulindac Enhances Tumor Necrosis Factor-α-mediated Apoptosis of Lung Cancer Cell Lines by Inhibition of Nuclear Factor-κB by BERMAN, Kevin S, VERMA, Udit N, HARBURG, Gwyndolen, MINNA, John D, COBB, Melanie H, GAYNOR, Richard B

“…Programmed cell death (apoptosis) is induced by certain anticancer therapies, and resistance to apoptosis is a major mechanism by which tumors evade these…”
Get full text

Efficacy of sequential treatment of HCT116 colon cancer monolayers and xenografts with docetaxel, flavopiridol, and 5-fluorouracil by Guo, Jun, Zhou, An-wu, Fu, Yu-cai, Verma, Udit N, Tripathy, Debu, Frenkel, Eugene P, Becerra, Carlos R

“…Aim： Clinical treatment of solid tumors with docetaxel, flavopiridol, or 5-fluorouracil （5-FU） often encounters undesirable side effects and drug resistance…”
Get full text

Randomized trial of irinotecan and cetuximab (IC) versus irinotecan, cetuximab and ramucirumab (ICR) as 2nd line therapy of advanced colorectal cancer (CRC) following oxaliplatin and bevacizumb based therapy: Result of E7208 by Hochster, H., Catalano, Paul J., O'Dwyer, Peter J., Mitchell, Edith P., Jill Cohen, Deirdre, Andrew Faller, Bryan, Kortmansky, Jeremy S., Mehta Kircher, Sheetal, Lacy, Jill, Lenz, Heinz-Josef, Verma, Udit N., Bowen Benson, Al

Get full text

When Phenotype Does Not Match Genotype—The Importance of Returning to the Raw Data by Wachsmann, Megan B., Verma, Udit N., Arriaga, Yull E., Hammer, Suntrea T., Oliver, Dwight

Get full text

Cells lacking IKKα show nuclear cyclin D1 overexpression and a neoplastic phenotype: role of IKKα as a tumor suppressor by Kwak, Youn-Tae, Radaideh, Sofyan M, Ding, Lianghao, Li, Rui, Frenkel, Eugene, Story, Michael D, Girard, Luc, Minna, John, Verma, Udit N

“…The catalytic subunits of IκB kinase (IKK) complex, IKKα and IKKβ, are involved in activation of NF-κB and in mediating a variety of other biological…”
Get full text

Nuclear role of I kappa B Kinase-gamma/NF-kappa B essential modulator (IKK gamma/NEMO) in NF-kappa B-dependent gene expression by Verma, Udit N, Yamamoto, Yumi, Prajapati, Shashi, Gaynor, Richard B

“…The I kappa B kinase (IKK) complex, which is composed of the two kinases IKK alpha and IKK beta and the regulatory subunit IKK gamma/nuclear factor-kappa B…”
Get full text

IκB Kinase α Regulates Subcellular Distribution and Turnover of Cyclin D1 by Phosphorylation by Kwak, Youn-Tae, Li, Rui, Becerra, Carlos R., Tripathy, Debu, Frenkel, Eugene P., Verma, Udit N.

“…IκB kinases (IKKs), IKKα and IKKβ, with a regulatory subunit IKKγ/NEMO constitute a high molecular weight IKK complex that regulates NF-κB activity. Although…”
Get full text

Phase I dose escalation study with irinotecan, capecitabine, epirubicin, and granulocyte colony-stimulating factor support for patients with solid malignancies by Becerra, Carlos R, Verma, Udit N, Tran, Hia T, Tavana, Denise, Williams, Noelle S, Frenkel, Eugene P

“…Preclinical studies using sequences of topoisomerase I and II inhibitors suggested synergism; preliminary clinical studies, resulting in enhanced antitumor…”
Get full text

Differences in clinical outcomes in young-onset colorectal cancer based on ethnicity in an NCI designated comprehensive cancer center by Fangman, Benjamin David, Haff, Stephen, Scielzo, Shannon, Sanjeevaiah, Aravind, Verma, Udit N., Cox, John Vernon, Kainthla, Radhika, Beg, Muhammad Shaalan, Kazmi, Syed Mohammad Ali

“…Abstract only 3605 Background: Ethnic disparities can impact clinical outcomes of young-onset colorectal cancer (CRC) patients. We aimed to determine if…”
Get full text

Interaction between regorafenib and warfarin therapy by Beg, Muhammad S., Khosama, Leticia, Conley, Stefanie, Arriaga, Yull Edwin, Syed, Samira K., Karri, Sirisha, Verma, Udit N.

“…Abstract only 651 Background: Regorafenib is an oral multi kinase inhibitor with clinical activity in colorectal cancer, gastrointestinal stromal tumors and…”
Get full text

The effects of pioglitazone treatment on pancreatic cancer-related insulin resistance by Stern, Jennifer, Arriaga, Yull Edwin, Gupta, Arjun, Verma, Udit N., Karri, Sirisha, Syed, Samira K., Khosama, Leticia, Mansour, John C., Scherer, Philipp, Beg, Muhammad Shaalan

“…Abstract only e15752 Background: Insulin resistance (IR) in pancreatic cancer (PC) patients is associated with cachexia and poor outcome. Pioglitazone (PIO)…”
Get full text

Randomized trial of irinotecan and cetuximab (IC) versus irinotecan, cetuximab and ramucirumab (ICR) as 2nd line therapy of advanced colorectal cancer (CRC) following oxaliplatin and bevacizumb based therapy: Result of E7208 by Hochster, Howard S., Catalano, Paul J., O'Dwyer, Peter J., Mitchell, Edith P., Cohen, Deirdre Jill, Faller, Bryan Andrew, Kortmansky, Jeremy S., Kircher, Sheetal Mehta, Lacy, Jill, Lenz, Heinz-Josef, Verma, Udit N., Benson, Al Bowen

“…Abstract only…”
Get full text

Impact of palliative care consults on racial disparity in do-not resuscitation (DNR) orders at an urban safety net hospital by Bhulani, Nizar, Gupta, Arjun, Paulk, M. Elizabeth, Donnell, Kiauna, Harvey, Valorie, Cox, Joan, Cox, John Vernon, Verma, Udit N., Sanjeevaiah, Aravind, Cheedella, Naga Koteswari, Khosama, Leticia, Arriaga, Yull Edwin, Syed, Samira K., Kazmi, Syed Mohammad Ali, Beg, Muhammad Shaalan

“…Abstract only…”
Get full text

O-030Randomized trial of irinotecan and cetuximab (IC) versus irinotecan, cetuximab and ramucirumab (ICR) as 2nd line therapy of advanced colorectal cancer (CRC) following oxaliplatin and bevacizumb based therapy: Result of E7208 by Hochster, H, Catalano, Paul J, O'Dwyer, Peter J, Mitchell, Edith P, Jill Cohen, Deirdre, Andrew Faller, Bryan, Kortmansky, Jeremy S, Mehta Kircher, Sheetal, Lacy, Jill, Lenz, Heinz-Josef, Verma, Udit N, Bowen Benson III, Al

Get full text

Prescribing patterns for FOLFIRINOX in the real world by Guenther, Chad Michael, Bhulani, Nizar, Korenke, Adam, Li, Jenny Jing, Khosama, Leticia, Syed, Samira K., Kazmi, Syed Mohammad Ali, Cheedella, Naga Koteswari, Karri, Sirisha, Lohrey, Jay, Sanjeevaiah, Aravind, Verma, Udit N., Cox, John Vernon, Arriaga, Yull Edwin, Beg, Muhammad Shaalan

“…Abstract only 463 Background: FOLFIRINOX therapy is associated with improved outcome in patients with gastrointestinal cancers. The regimen can be associated…”
Get full text

A phase II, randomized, double-blinded, placebo-controlled study of simtuzumab or placebo in combination with FOLFIRI for the second line treatment of metastatic KRAS mutant colorectal adenocarcinoma by Hecht, J. Randolph, Bendell, Johanna C., Vyushkov, Dmitry, Bencardino, Katia, Verma, Udit N., Yang, Yingsi, Thai, Dung Luong

“…Abstract only…”
Get full text

Palliative care and end-of-life health care utilization of pancreatic cancer patients at an urban safety-net hospital by Bhulani, Nizar, Paulk, M. Elizabeth, Gupta, Arjun, Donnell, Kiauna, Harvey, Valorie, Cox, Joan, Cox, John Vernon, Karri, Sirisha, Verma, Udit N., Sanjeevaiah, Aravind, Cheedella, Naga Koteswari, Khosama, Leticia, Arriaga, Yull Edwin, Syed, Samira K., Kazmi, Syed Mohammad Ali, Korenke, Adam, Beg, Muhammad Shaalan

“…Abstract only 489 Background: There has been an increase in Palliative care utilization in cancer patients. We examined trends of palliative care and intensive…”
Get full text